TechWald Holding S.p.A.
VC Fund
Milan, Italy
TechWald Holding S.p.A. is a VC fund in Milan focused on Health Care and Medical Device. TechWald Holding is a participation holding company investing in Medical Technologies
- Total investments:
- 10
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries TechWald Holding S.p.A. invests in
Stages TechWald Holding S.p.A. invests in
Countries TechWald Holding S.p.A. invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $3.6M–$7.1M
- Series B
- $8.5M–$48M
- Series C
- $9.3M–$60M
Investment Focus
Industry
- Health Care 7 (70%)
- Medical Device 5 (50%)
- Medical 4 (40%)
- Biotechnology 2 (20%)
- Software 1 (10%)
Stage
- Series A 3 (30%)
- Series B 3 (30%)
- Series C 2 (20%)
- Convertible Note 1 (10%)
- Venture - Series Unknown 1 (10%)
Country
- Israel 4 (40%)
- United States 2 (20%)
- Switzerland 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Luca Binda PhD MBA
Managing Partner & Investment Director
|
Managing Partner & Investment Director | Total investments: 15 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
RapidPulse
|
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry | $48M / Series B / Jul 16, 2026 | |
NitiNotes
|
Nitinotes has developed the EndoZipTM, a fully automated, operator independent gastroscopic suturing system, allowing gastroenterologists as well as surgeons to bring a durable solution to their patients. The procedure creates an effect of stomach volume restriction and motility impair - both are needed to help obese patients reducing weight. | $9.3M / Series C / Dec 23, 2024 | |
Lymphatica Medtech
|
Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle. | $19.6M / Series B / Oct 08, 2024 | |
SentiAR
|
SentiAR is digital health, software device company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, we are developing the first 3D visualization platform using real-time holography of the patient's anatomy and catheter location, "floating" over the patients, with a goal toprovide the clinician and patient a faster, safer delivery of care.SentiAR’s mission is to transform the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.The visualization is fully controllable “hands-free” by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment. SentiAR is developing the platform for eventual FDA submission. | $8.5M / Series B / Apr 11, 2023 | |
SoniVie
|
SoniVie is developing an advanced denervation solution to treat pulmonary hypertension. | $60M / Series C / Jan 09, 2023 | |
Beyeonics
|
Beyeonics Surgical technologies began operating in 2012, led by a team of Elbit Systems senior engineers with a mission to revolutionize the visualization and information presented during surgery. Future products include visualization systems for other surgical applications as well as solutions for spine surgery, minimal invasive procedures,robotic surgery and use in cardiovascular catheterization labs. Operating from Israel, Beyeonics is working in collaboration with Prof. Anat Lowenstein the Head of Ophthalmic Department and Prof. Adiel Barak the Head of the Retina Department in Tel Aviv Sourasky Medical Center and with Dr. Pravin Dugel managing partner at Retinal Consultants of Arizona. | $26M / Venture - Series Unknown / Oct 03, 2021 | |
|
SentiAR
|
SentiAR is digital health, software device company adding a new dimension to clinical practice in interventional procedures. Spun out of Washington University, we are developing the first 3D visualization platform using real-time holography of the patient's anatomy and catheter location, "floating" over the patients, with a goal toprovide the clinician and patient a faster, safer delivery of care.SentiAR’s mission is to transform the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.The visualization is fully controllable “hands-free” by the clinician, providing an ergonomic breakthrough for the treatment and analysis of cardiac arrhythmias within an interventional catheter lab environment. SentiAR is developing the platform for eventual FDA submission. | $5.1M / Series A / Apr 13, 2021 | |
|
NitiNotes
|
Nitinotes has developed the EndoZipTM, a fully automated, operator independent gastroscopic suturing system, allowing gastroenterologists as well as surgeons to bring a durable solution to their patients. The procedure creates an effect of stomach volume restriction and motility impair - both are needed to help obese patients reducing weight. | $7.1M / Series A / Mar 25, 2020 | |
Bendit
|
Bendit is a medical company that develops and manufactures innovative catheters based on a unique bending technology, enabling extensive steering abilities in micro diameter and conventional catheter wires and tubes. The company is a joint venture between three experienced groups from production, quality & regulation, and development in themedical field. | $2M / Convertible Note / Jun 01, 2018 | |
|
Bendit
|
Bendit is a medical company that develops and manufactures innovative catheters based on a unique bending technology, enabling extensive steering abilities in micro diameter and conventional catheter wires and tubes. The company is a joint venture between three experienced groups from production, quality & regulation, and development in themedical field. | $3.6M / Series A / Sep 03, 2017 |
Co-Investors
Cultivation Capital
2 deals together
Harmonix Fund
2 deals together
Indaco Venture Partners
2 deals together
MTIP AG
2 deals together
Harmonix Fund
2 deals together
VCapital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does TechWald Holding S.p.A. invest in?
TechWald Holding S.p.A. invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is TechWald Holding S.p.A.'s check size?
TechWald Holding S.p.A. typically joins rounds of $3.6M–$7.1M at Series A, $8.5M–$48M at Series B and $9.3M–$60M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds TechWald Holding S.p.A. participates in.
How do I contact TechWald Holding S.p.A.?
Public channels for TechWald Holding S.p.A. include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at TechWald Holding S.p.A.?
The team at TechWald Holding S.p.A. includes Luca Binda PhD MBA (Managing Partner & Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
